DAIICHI-SANKYO-EUROPE
8.12.2022 08:01:35 CET | Business Wire | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3
Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C level, the lower their cardiovascular risk.4
“The positive results from the CLEAR Outcomes Trial represents a pivotal step towards reducing the impact of CVD in Europe for patients who are currently at high risk of heart attack and stroke,” said Professor Kausik Ray, Professor of Public Health and President of the European Atherosclerosis Society, Honorary Consultant Cardiologist, Director ICTU Global and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. “I am very excited to see more data from the trial over the coming months and better understand how bempedoic acid can continue to help clinicians bring LDL-C levels of patients to guideline-recommended goals and thus reduce the impact of cholesterol on CV health in Europe.”
“With 10,000 lives lost everyday to CVD in Europe, we are truly encouraged by this new data, which demonstrates that bempedoic acid does reduce the risk of serious CV events for patients who are at high-risk of experiencing a heart attack or stroke,”1,4 said Dr Stefan Seyfried, Vice President Medical Affairs Specialty Medicines, Daiichi Sankyo Europe GmbH. “We look forward to sharing additional analyses and insights, as well as working closely with the scientific and clinical communities, to better understand how the data can support their care for CVD patients across Europe.”
CLEAR Outcomes was a Phase 3, event-driven, randomised, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduced the risk of CV events in patients with or who are at high risk for ASCVD with documented statin intolerance and elevated LDL-C levels (fasting blood LDL-C ≥ 100 mg/dL (2.6 mmol/L)).3 The study, which was fully enrolled in August 2019, included 14,014 patients at over 1,200 sites in 32 countries. Patients had at least 36 months of follow-up.3
-ENDS-
About bempedoic acid
Bempedoic acid (commercialised in the European Economic Area, Turkey and Switzerland as NILEMDO®▼) is a first-in-class, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.2,5 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.2
Bempedoic acid has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies. Due to its unique mechanism of action, bempedoic acid is not activated in skeletal muscle.
Daiichi Sankyo Europe has licensed exclusive commercialisation rights to bempedoic acid in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realise our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”
For more information, please visit www.daiichisankyo.com
▼ This medicinal product is subject to additional monitoring.
____________________________________________________
2 European Medicines Agency. NILEMDO Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf. Last accessed December 2022.
3 Nicholls, S.J., et.al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021. 235: 104–112.
4 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemia. Eur Heart J. 2020. 41(1):111–188.
5 SwissMedic. NILEMDO (bempedoic acid) Product Information for Human Medicinal Products. Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-nilemdo.html. Last accessed December 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005816/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Data Platform Powers Data Operations for Super Bowl LX27.1.2026 14:00:00 CET | Press release
Intelligent Data Infrastructure Elevates the Fan Experience at Levi’s® Stadium NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it is powering data operations for Super Bowl LX. As the Official Intelligent Data Infrastructure Partner of the San Francisco 49ers and the National Football League (NFL), NetApp provides the enterprise-grade data platform that powers the digital and physical experiences for football fans, whether watching the game from Levi’s® Stadium or from their couch on the other side of the world. “The world runs on data, even in an industry as physical as sports,” said Gabie Boko, Chief Marketing Officer at NetApp. “Optimizing data for innovation isn’t just about where the data lives, but also about how it moves. There is no place where that will be on display more clearly than Levi’s® Stadium during the Super Bowl. While the stadium is not a traditional data center, during a game, it transforms into an interactive data center b
REVEAL GENOMICS Aligns Founder Leadership With Priorities to Support Long-term Growth, Scientific Excellence, and Global Partnerships27.1.2026 13:43:00 CET | Press release
The company appoints Joel Parker, Ph.D., as Chief Scientific Officer; Ana Vivancos, Ph.D., as Director of NGS and Genomic Technologies; and Aleix Prat, M.D., Ph.D., as Chairman of the Board of Directors.Leadership roles are assumed by the company’s co-founders, who strengthen governance and alignment across scientific, clinical, and strategic priorities.The strengthened leadership framework supports global scientific progress and clinical adoption of the genomic assays of REVEAL GENOMICS. REVEAL GENOMICS, a Barcelona-based biotechnology company that advances precision oncology through biomarker innovation, today announced a strengthened leadership framework with several senior appointments. These appointments underscore the company’s commitment to scientific excellence, technological rigor, and clinical impact, and they seek to support the continued development, validation, and global adoption of the company’s genomic assays. This press release features multimedia. View the full releas
Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease27.1.2026 12:00:00 CET | Press release
75% of patients have completed the Week 78 Last Study VisitTopline results expected in mid-2026 Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that 75% of patients currently enrolled in its ongoing Phase 2b clinical study ACTIVATE (ClinicalTrials.gov identifier: NCT05819359) have completed the double-blind treatment period through week 78. This operational milestone represents a significant step toward the completion of the ACTIVATE study, which is evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The date of the Last Patient, Last Visit (LPLV) is anticipated in April 2026, with topline results on track to be released in mid-2026. “We look forward to presenting data from our Phase 2b study. BIA 28-6156 is the leading asset in GBA-PD, and clinical out
Libraesva and Cyber Guru Announce Strategic Combination to Create a Leading European Human-Centric Cybersecurity Provider27.1.2026 11:00:00 CET | Press release
The combination of two Italian cybersecurity leaders with strong international footprints creates a unique European player delivering an integrated portfolio of Email Security and Security Awareness Training to reduce human cyber risk end-to-end. Cyber Guru and Libraesva today announced a strategic combination that brings together two highly complementary Italian cybersecurity companies to form a new European leader in human-centric cyber protection. The combined group will offer organisations an integrated approach to defending against email-based threats, social engineering, and human-targeted attacks, integrating advanced technology with behavioural resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127531600/en/ Cyber threats are evolving rapidly, with attackers focusing less on infrastructure and more on the weak link in security – human behaviour. Phishing, business email compromise, smishing, QR-code attack
Europe’s First Meteorological Infrared Sounder Reveals the Atmosphere in 3D27.1.2026 10:30:00 CET | Press release
The first images from Europe’s pioneering meteorological infrared sounder were unveiled today at the EU Space Conference in Brussels, marking a major advance in the ability to monitor how the atmosphere evolves before and during severe weather. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127490399/en/ Full Earth disc image from the MTG-S Infrared Sounder showing a surface-temperature-sensitive channel, captured between 12:45 and 15:30 UTC on 15 November 2025. The image distinguishes land and sea surface temperatures as well as cloud-top temperatures, highlighting cloud structures and weather systems. Hot desert regions appear in red, while cold cloud tops are shown in blue. © Image: Data acquired on 15 November 2025 and processed by industrial partners Thales and OHB under the supervision of EUMETSAT and ESA. Visual produced by EUMETSAT. The images were captured by the Infrared Sounder (IRS) flying aboard Meteosat Thir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom